[
  {
    "ts": null,
    "headline": "Onco360® Has Been Selected as a Specialty Pharmacy Partner for LYNOZYFIC™ (linvoseltamab-gcpt)",
    "summary": "LOUISVILLE, Ky., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a national pharmacy partner by Regeneron Pharmaceuticals for Lynozyfic™ (linvoseltamab-gcpt), which has been has granted accelerated approval by the Food and Drug Administration to treat adult patients with relapsed or refractory (R/R) multiple myeloma (MM) who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulato",
    "url": "https://finnhub.io/api/news?id=2798e7ff7ff09fc031cb886933b2683c6ff1c58c14f4788b65939871970404d0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754339400,
      "headline": "Onco360® Has Been Selected as a Specialty Pharmacy Partner for LYNOZYFIC™ (linvoseltamab-gcpt)",
      "id": 136205996,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "LOUISVILLE, Ky., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a national pharmacy partner by Regeneron Pharmaceuticals for Lynozyfic™ (linvoseltamab-gcpt), which has been has granted accelerated approval by the Food and Drug Administration to treat adult patients with relapsed or refractory (R/R) multiple myeloma (MM) who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulato",
      "url": "https://finnhub.io/api/news?id=2798e7ff7ff09fc031cb886933b2683c6ff1c58c14f4788b65939871970404d0"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
    "summary": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=4208cc5d688c2cfe23b99f212cec7e9a9bcf269a3eb5b56e662953f6ec171da3",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754325960,
      "headline": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
      "id": 136223702,
      "image": "",
      "related": "REGN",
      "source": "MarketWatch",
      "summary": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=4208cc5d688c2cfe23b99f212cec7e9a9bcf269a3eb5b56e662953f6ec171da3"
    }
  },
  {
    "ts": null,
    "headline": "Manufacturing issues at Novo facility disrupt Regeneron drug review",
    "summary": "Issues were picked up during an FDA inspection of Novo Nordisk-owned Catalent’s mammoth filling plant.",
    "url": "https://finnhub.io/api/news?id=8f812e45e1ab86fec6d79aeef8003d1a86f3f4e20c1f8e3216d9932cf787a2e9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754307397,
      "headline": "Manufacturing issues at Novo facility disrupt Regeneron drug review",
      "id": 136198203,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Issues were picked up during an FDA inspection of Novo Nordisk-owned Catalent’s mammoth filling plant.",
      "url": "https://finnhub.io/api/news?id=8f812e45e1ab86fec6d79aeef8003d1a86f3f4e20c1f8e3216d9932cf787a2e9"
    }
  },
  {
    "ts": null,
    "headline": "Putnam Large Cap Value Fund Q2 2025 Commentary",
    "summary": "Putnam Large Cap Value Fund posted a positive return and outperformed its benchmark, the Russell 1000 Value Index. Read more here.",
    "url": "https://finnhub.io/api/news?id=1ef9fb42bf3abda571edf6ffa36b63367d13511c955be46f8b113e0d257665ca",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754280540,
      "headline": "Putnam Large Cap Value Fund Q2 2025 Commentary",
      "id": 136196579,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1979013200/image_1979013200.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "Putnam Large Cap Value Fund posted a positive return and outperformed its benchmark, the Russell 1000 Value Index. Read more here.",
      "url": "https://finnhub.io/api/news?id=1ef9fb42bf3abda571edf6ffa36b63367d13511c955be46f8b113e0d257665ca"
    }
  }
]